ShadowDragon Sets a New Standard in Link Analysis, Monitoring, & OSINT by Launching Multilingual Suite
10.2.2025 16:21:00 CET | Business Wire | Press release
ShadowDragon Horizon - Empowering Global Investigations in Spanish, French, Italian, German—and More Languages on the Horizon
ShadowDragon, a leader in digital investigations and open-source intelligence (OSINT) solutions, today announced the launch of Horizon in multiple languages. Effective immediately, this flagship tool—previously available in English—is now fully localized in Spanish, French, Italian, and German, with additional languages slated for release in the coming months. By expanding language support, ShadowDragon becomes the first in the industry to offer a comprehensive suite of advanced OSINT capabilities designed to serve a wide range of global investigators, law enforcement, and intelligence agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207507777/en/
“ShadowDragon has always led the way in building robust OSINT solutions that keep pace with today’s complex global landscape,” said Daniel Clemens, CEO and Founder of ShadowDragon. “By providing our solutions in multiple languages, we reaffirm our commitment to supporting investigations, data scientists, business intelligence, and robust due diligence processes around the world—particularly in regions where language barriers have historically affected use of advanced data visualization tools. We spent a long time building this component to allow analysts to collect, analyze and investigate data and tell the story in their own language.”
Why This Matters for Global Investigations
- Accelerated Case Resolution
With user interfaces, documentation, and workflows now available in Spanish, French, Italian, and German, local and cross-border investigative teams can focus on gathering actionable intelligence — leading to quicker resolutions. - Enhanced Collaboration Across Borders
International investigations often involve partners from diverse linguistic backgrounds. Harmonizing data and workflows in multiple languages removes communication hurdles, yielding more reliable intelligence and smoother cooperation. - Industry-First Multilingual OSINT Leader
As the first OSINT provider to fully localize its core offerings across these major languages, ShadowDragon sets a new standard for accessibility and operational readiness in digital investigations.
Commitment to Global Customers
This launch underscores ShadowDragon’s long-term dedication to serving a diverse, international client base that requires cutting-edge OSINT solutions. Users can rely on in-language technical support, ongoing product updates, and comprehensive educational resources to help them get the most out of these new language capabilities from day one.
About ShadowDragon
ShadowDragon provides comprehensive digital tools for modern investigations, open source intelligence collection, tailored monitoring, and investigative platform for cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open-source intelligence (OSINT) from over 200 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for good.”
For more information on ShadowDragon’s multilingual product suite or upcoming language releases, visit www.shadowdragon.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207507777/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom